BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 34685504)

  • 21. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
    Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
    Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
    Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
    Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer.
    Yan M; Li X; Tong D; Han C; Zhao R; He Y; Jin X
    Oncol Rep; 2016 Jul; 36(1):65-71. PubMed ID: 27108696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
    Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
    Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOCAD/miR-491-5p, downregulated by EGR1, function as tumor suppressor by inhibiting the proliferation and migration of gastric cancer cells.
    Sun R; Liu Z; Lv Y; Yang Y; Yang Y; Xiang Y; Jiang Q; Zhao C; Lv M; Zhang J; Zhang J; Ding C; Zhou D
    Prog Biophys Mol Biol; 2022 Dec; 176():25-37. PubMed ID: 35788362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induced expression of miR-1250-5p exerts tumor suppressive role in triple-negative breast cancer cells.
    Shuaib M; Kumar S
    J Cell Biochem; 2023 Feb; 124(2):282-293. PubMed ID: 36548440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
    Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
    Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.
    Wang L; Kang FB; Wang J; Yang C; He DW
    Anticancer Drugs; 2019 Mar; 30(3):225-232. PubMed ID: 30334817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.
    Wong CK; Gromisch C; Ozturk S; Papageorgis P; Abdolmaleky HM; Reinhard BM; Thiagalingam A; Thiagalingam S
    Cancer Biol Ther; 2019; 20(8):1113-1120. PubMed ID: 30922194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CircFAM64A enhances cellular processes in triple-negative breast cancer by targeting the miR-149-5p/CDT1 axis.
    Maimaiti Y; Zhang N; Zhang Y; Zhou J; Song H; Wang S
    Environ Toxicol; 2022 May; 37(5):1081-1092. PubMed ID: 35048507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer.
    Pang Y; Liu J; Li X; Xiao G; Wang H; Yang G; Li Y; Tang SC; Qin S; Du N; Zhang H; Liu D; Sun X; Ren H
    J Cell Mol Med; 2018 Dec; 22(12):6262-6274. PubMed ID: 30324719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
    Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
    Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer.
    Kong P; Chen L; Yu M; Tao J; Liu J; Wang Y; Pan H; Zhou W; Wang S
    Cell Death Dis; 2018 Oct; 9(11):1059. PubMed ID: 30333478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring specific prognostic biomarkers in triple-negative breast cancer.
    Bao C; Lu Y; Chen J; Chen D; Lou W; Ding B; Xu L; Fan W
    Cell Death Dis; 2019 Oct; 10(11):807. PubMed ID: 31649243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
    Bai X; Han G; Liu Y; Jiang H; He Q
    Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/MAPK pathway in triple negative breast cancer.
    Yu B; You W; Chen G; Yu Y; Yang Q
    Cell Cycle; 2019 Oct; 18(20):2641-2650. PubMed ID: 31411515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
    Son D; Kim Y; Lim S; Kang HG; Kim DH; Park JW; Cheong W; Kong HK; Han W; Park WY; Chun KH; Park JH
    Cancer Lett; 2019 Jul; 454():224-233. PubMed ID: 31004703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.